IRVING, Texas, Dec. 4, 2017 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of three abstracts, including a spotlight poster discussion and two poster sessions, for presentation at the 2017 San Antonio Breast Cancer Symposium (SABCS) annual meeting, being held December 5-9, in San Antonio, Texas. Two of the studies were conducted in collaboration with industry-leading academic and clinical institutions employing the company's proprietary Caris Molecular Intelligence® Comprehensive Genomic Profiling Plus (CGP+) tumor profiling platform, and it's revolutionary and unbiased profiling platform, ADAPT Biotargeting System™.
"The studies presented at SABCS further highlight the need for more informative biomarkers associated to immune checkpoint inhibitors to increase the effectiveness of immunotherapy in advanced breast cancer, and that our ADAPT Biotargeting system has demonstrated the ability to identify tumor profiles that would not respond to the standard of care," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences. "Our platforms help both clinicians and biopharmaceutical companies better understand cancer biology and ultimately increase the chances for successful outcomes for cancer patients. We are excited to be presenting a multitude of supporting data during this year's SABCS."
|
Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer |
||
|
Spotlight Session 6: Immuno Oncology: Immune Metastatic / Poster Discussion |
||
|
Abstract #1416, Poster #PD6-03 |
||
|
Thursday, December 7, 5:00 – 7:00 p.m. CST |
||
|
Stars at Night Ballroom 3 & 4 - 3rd Level |
||
Summary: Following FDA approval of the immune checkpoint blocker agent pembrolizumab for all MSI (microsatellite instability)-high solid tumors, this study aimed to explore the incidence of three biomarkers – MSI, PD-1 ligand (PD-L1) status and tumor mutational load (TML) – in possible relationship to ICB activity in invasive breast cancers. A total of 9,627 breast cancer cases were queried from the Caris Life Sciences database. Cases were identified with elevated PD-L1 and either MSI-H or high TML tumors, indicating a population of breast cancer patients who may be strong candidates to benefit from pembrolizumab. Notably, these cases were seen most often in triple-negative breast cancer, the subtype most in need of new therapeutic agents.
|
Polyligand profiling differentiates cancer patients according to their benefit of treatment |
||
|
Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies |
||
|
Abstract #1382, Poster #P2-09-09 |
||
|
Thursday, December 7, 7:00 – 9:00 a.m. CST |
||
|
Hall 1 |
||
Summary: Caris' ADAPT Biotargeting System outperformed the standard immunohistochemistry (IHC) assay for HER2 status in differentiating patients who did or did not benefit from trastuzumab therapy. These results represent a promising step toward the development of a diagnostic adjunct that may be used in conjunction with standard HER2 testing to refine patient selection for anti-HER2 targeted therapies.
|
Polyligand profiling and target identification from formalin-fixed- paraffin embedded HER2+ breast cancer specimens |
||
|
Poster Session 5: Tumor Cell and Molecular Biology: Systems Biology of Breast Cancer |
||
|
Abstract #1412, Poster #P5-08-03 |
||
|
Friday, December 8, 5:00 – 7:00 p.m. CST |
||
|
Hall 1 |
||
Summary: The study reports extended capabilities of the ADAPT Biotargeting System for target identification directly from formalin-fixed-paraffin embedded (FFPE) tissues using aptamer libraries enriched toward HER2+ breast cancer. Proteins with known roles in HER2+ breast cancer along with several potentially novel targets not previously associated with HER2 positivity were identified. By nature of its extreme molecular complexity and its ability to be iteratively or "trained," toward phenotypes of interest, the ADAPT Biotargeting System can be deployed to advance precision medicine by identifying predictive biomarkers and drug targets in complex interactomes in FFPE tissue.
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation, and the world's leading immunotherapy diagnostic expert. Caris Molecular Intelligence®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment decisions. The ADAPT Biotargeting System™, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
187024@email4pr.com
Tel: +1-508-280-6592 / +1-646-536-7006
SOURCE Caris Life Sciences